Squarepoint’s Mereo BioPharma MREO Stock Holding History

Squarepoint’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-257,700	Closed	-$595K	–	4385
2023 Q4	$595K	Buy	+257,700	New	+$493K	﹤0.01%	2880

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Squarepoint's MREO Position: Q4 2025 in Review

Squarepoint sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 30,055 shares — an estimated $61.9K sold.

Squarepoint first reported a position in MREO in Q1 2021 and held it in 8 quarters. The position peaked at $157K in Q1 2024. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

Squarepoint reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
Squarepoint sold 30,055 Mereo BioPharma shares in Q4 2025, an estimated $61.9K.
Squarepoint first reported a position in Mereo BioPharma in Q1 2021 and held it in 8 quarters.
Squarepoint's Mereo BioPharma position peaked at $157K in Q1 2024.
70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.